CN104126124A - 用于慢性hbv患者的反应预测和疗法监测的hbv免疫复合物 - Google Patents

用于慢性hbv患者的反应预测和疗法监测的hbv免疫复合物 Download PDF

Info

Publication number
CN104126124A
CN104126124A CN201380010278.0A CN201380010278A CN104126124A CN 104126124 A CN104126124 A CN 104126124A CN 201380010278 A CN201380010278 A CN 201380010278A CN 104126124 A CN104126124 A CN 104126124A
Authority
CN
China
Prior art keywords
hbv
amount
immune complex
experimenter
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380010278.0A
Other languages
English (en)
Chinese (zh)
Inventor
U·克劳斯
B·希普
V·P·格鲁纳特
B·乌普迈尔
U·洛帕汀
A·德涅特
H·里辛克
H·扎伊捷尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Academisch Medisch Centrum Bij de Universiteit van Amsterdam
Original Assignee
F Hoffmann La Roche AG
Academisch Medisch Centrum Bij de Universiteit van Amsterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Academisch Medisch Centrum Bij de Universiteit van Amsterdam filed Critical F Hoffmann La Roche AG
Publication of CN104126124A publication Critical patent/CN104126124A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380010278.0A 2012-02-20 2013-02-18 用于慢性hbv患者的反应预测和疗法监测的hbv免疫复合物 Pending CN104126124A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12156192.2 2012-02-20
EP12156192.2A EP2629096A1 (en) 2012-02-20 2012-02-20 HBV immunocomplexes for response prediction and therapy monitoring of chronic HBV patients
PCT/EP2013/053150 WO2013124229A1 (en) 2012-02-20 2013-02-18 Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients

Publications (1)

Publication Number Publication Date
CN104126124A true CN104126124A (zh) 2014-10-29

Family

ID=47757571

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380010278.0A Pending CN104126124A (zh) 2012-02-20 2013-02-18 用于慢性hbv患者的反应预测和疗法监测的hbv免疫复合物

Country Status (7)

Country Link
US (1) US20150192583A1 (enExample)
EP (2) EP2629096A1 (enExample)
JP (1) JP2015508892A (enExample)
CN (1) CN104126124A (enExample)
CA (1) CA2863106A1 (enExample)
HK (1) HK1203616A1 (enExample)
WO (1) WO2013124229A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115466802A (zh) * 2022-10-28 2022-12-13 北京大学 Tp53bp2在调控干扰素信号通路及抗病毒中的用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6738319B2 (ja) * 2015-03-30 2020-08-12 雅史 溝上 インターフェロン治療効果予測方法及びそれを用いたｂ型肝炎患者の治療用医薬組成物
EP3322820A1 (en) * 2015-07-15 2018-05-23 H. Hoffnabb-La Roche Ag Biomarkers for hbv treatment response
WO2018087715A1 (en) * 2016-11-11 2018-05-17 Melbourne Health An assay for determining hepatitis b clearance
TW201928064A (zh) * 2017-12-21 2019-07-16 紐西蘭商紐西蘭健康創新中心管理有限公司 B型肝炎病毒之突變分析方法及其應用
WO2019213619A1 (en) * 2018-05-04 2019-11-07 Abbott Laboratories Hbv diagnostic, prognostic, and therapeutic methods and products
CN110564894B (zh) * 2019-09-10 2023-04-07 深圳市罗湖区人民医院 干扰物对荧光定量pcr检测hbv dna的干扰评价方法
CN111474187A (zh) * 2020-04-09 2020-07-31 三峡大学 一种免疫电镜免疫反应盒

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1365286A (zh) * 1999-06-22 2002-08-21 希龙公司 治疗慢性乙型肝炎病毒感染的方法
CN1495193A (zh) * 2002-07-19 2004-05-12 余宙耀 一种重组人源性抗乙肝表面抗原（HBsAg）Fab抗体及其制取方法
CN1874787A (zh) * 2003-08-29 2006-12-06 莱因新生物技术工艺和产品有限公司 预防/治疗hbv感染和hbv介导疾病的组合物
CN1906488A (zh) * 2003-11-12 2007-01-31 Hbv诊断治疗股份有限公司 涉及乙型肝炎感染的方法和工具

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726011A (en) * 1994-03-31 1998-03-10 Virginia Commonwealth University Method for diagnosing chronic hepatitis B virus infection
US20090170926A1 (en) * 2004-03-31 2009-07-02 Monash Univeristy Antiviral agents
ES2368776T3 (es) * 2007-05-08 2011-11-22 F. Hoffmann-La Roche Ag MÉTODO PARA LA DETECCIÓN DE ANTICUERPOS ESPECÍFICOS DE LA CLASE DE INMUNOGLOBULINA G (IgG).
AU2010236606A1 (en) * 2009-04-14 2011-11-03 Merck Sharp & Dohme Corp. Interferon-alfa sensitivity biomarkers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1365286A (zh) * 1999-06-22 2002-08-21 希龙公司 治疗慢性乙型肝炎病毒感染的方法
CN1495193A (zh) * 2002-07-19 2004-05-12 余宙耀 一种重组人源性抗乙肝表面抗原（HBsAg）Fab抗体及其制取方法
CN1874787A (zh) * 2003-08-29 2006-12-06 莱因新生物技术工艺和产品有限公司 预防/治疗hbv感染和hbv介导疾病的组合物
CN1906488A (zh) * 2003-11-12 2007-01-31 Hbv诊断治疗股份有限公司 涉及乙型肝炎感染的方法和工具

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. DE NIET，ET AL.: "A NEW HBsAg/ANTI-HBs IMMUNE COMPLEX ASSAY PREDICTS HBeAG LOSS IN CHRONIC HEPATITIS B PATIENTS", 《HEPATOLOGY》 *
BART TAKKENBERG,ET AL.: "Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adeovir", 《JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115466802A (zh) * 2022-10-28 2022-12-13 北京大学 Tp53bp2在调控干扰素信号通路及抗病毒中的用途
CN115466802B (zh) * 2022-10-28 2023-12-12 北京大学 Tp53bp2在调控干扰素信号通路及抗病毒中的用途

Also Published As

Publication number Publication date
HK1203616A1 (en) 2015-10-30
WO2013124229A1 (en) 2013-08-29
EP2817631A1 (en) 2014-12-31
CA2863106A1 (en) 2013-08-29
EP2629096A1 (en) 2013-08-21
US20150192583A1 (en) 2015-07-09
JP2015508892A (ja) 2015-03-23

Similar Documents

Publication Publication Date Title
CN104126124A (zh) 用于慢性hbv患者的反应预测和疗法监测的hbv免疫复合物
JP5710699B2 (ja) オートタキシン測定による慢性肝疾患の検査方法および検査薬
JP6713478B2 (ja) Ｐｉｖｋａ−ｉｉの測定方法、及びｐｉｖｋａ−ｉｉ免疫測定試薬又はキットの製造方法
JP7216948B1 (ja) ＳＡＲＳ－ＣｏＶ－２の免疫測定方法及び免疫測定キット、並びにモノクローナル抗体又はその抗体断片
US11156610B2 (en) Methods for reducing interferences
WO2022265066A1 (ja) ＳＡＲＳ－ＣｏＶ－２の免疫測定方法及び免疫測定キット
US20220120737A1 (en) Method for detecting sars-cov-2-specific serum human immunoglobulins
CN111417854A (zh) 乙型肝炎病毒s抗原的测定方法和测定试剂盒
JP6048923B2 (ja) Ｂ型慢性肝炎の検出方法および検出キット
US20240377396A1 (en) Immunoassay method, specimen diluent, and immunochromatography kit
JP4346798B2 (ja) Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。
JP5856956B2 (ja) 血液検査方法
WO2022023461A1 (en) Improved epitope for detecting and/or quantifying autoantibodies against alpha-fetoprotein
JP2019053060A (ja) Ｂ型肝炎ウイルスコア抗体の免疫測定方法
EP3465217A1 (en) Method for serological detection of viral antigens
CN113196057A (zh) 病毒性肝癌的检测方法
CN120757639A (zh) 一种p-Tau217单分子检测试剂盒及其检测抗体
JP2025023504A (ja) セリンプロテアーゼの検出用または測定用試薬
JP2003083976A (ja) ＨＢｓ抗原測定試薬
WO2023068249A1 (ja) Ｉ型コラーゲン架橋ｎ－テロペプチドの測定試薬、その調製方法、及びそれを用いた免疫測定方法
CN114729935A (zh) 使用免疫反应的分析物的测量方法和测量试剂
CN120831486A (zh) 一种生物标志物组合及其应用
CN115616211A (zh) 一种抗肽基脯氨酰基顺反异构酶D-IgG抗体的检测试剂盒
HK1237876A1 (en) Methods for reducing interferences

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1203616

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20141029

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1203616

Country of ref document: HK